CONTRIBUTORS

Muscle and Neuromuscular Junction Disorders p. 1528-1533 December 2019, Vol.25, No.6 doi: 10.1212/01.CON.0000617300.12766.5b
CONTRIBUTORS
BROWSE ARTICLES

Nicholas E. Johnson, MD, MSc, FAAN Guest Editor

Vice Chair of Research, Neuromuscular Division Chief, Associate Professor of Neurology, Virginia Commonwealth University, Richmond, Virginia

Relationship Disclosure: Dr Johnson has served as a consultant for AMO Pharma; Asklepios BioPharmaceutical, Inc (AskBio); AveXis, Inc; Dyne Therapeutics; Fulcrum Therapeutics; ML Bio; and Vertex Pharmaceuticals Incorporated and has received personal compensation for speaking engagements from Sarepta Therapeutics and Strongbridge Biopharma plc. Dr Johnson has received research/grant support from AMO Pharma; AveXis, Inc; the Coalition to Cure Calpain 3; CSL Behring; Fulcrum Therapeutics; the Muscular Dystrophy Association; the Myotonic Dystrophy Foundation; the National Institute of Neurological Disorders and Stroke (K23NS091511-05; R01NS104010-01); Sarepta Therapeutics; and the US Food and Drug Administration (1RO1FD006071-02). Dr Johnson has received publishing royalties from the Charcot-Marie-Tooth Health Index and the Congenital and Childhood Myotonic Dystrophy Health Index.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Johnson discusses the unlabeled/investigational use of mexiletine for the treatment of myotonia and armodafinil and modafinil for the treatment of daytime sleepiness in myotonic dystrophy.

Anthony A. Amato, MD, FAAN

Distinguished Chair in Neurology, Chief of Neuromuscular Division, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School, Boston, Massachusetts

Relationship Disclosure: Dr Amato has received personal compensation as an associate editor for Neurology. Dr Amato has received research/grant support from Acceleron Pharma, Inc, National Institutes of Health (U01AR070498-01A1 and U24NS107154-01), Orphazyme, and Pharnext and royalties for authorship of Neuromuscular Disorders and Harrison’s Textbook of Internal Medicine from McGraw-Hill Education

Unlabeled Use of Products/Investigational Use Disclosure: Dr Amato discusses the unlabeled/investigational use of immunotherapy for the treatment of drug-induced inflammatory myopathies.

Russell J. Butterfield, MD, PhD, FAAN

Associate Professor of Pediatrics and Neurology, University of Utah, Salt Lake City, Utah

Relationship Disclosure: Dr Butterfield has received personal compensation for serving on the scientific advisory boards of Biogen and Sarepta Therapeutics. Dr Butterfield has received research grant support as principal investigator of studies from Acceleron Pharma, Inc; AveXis, Inc; Biogen; Capricor Therapeutics; Catabasis Pharmaceuticals; the National Institutes of Health and National Institute of Neurological Disorders and Stroke; Pfizer Inc; PTC Therapeutics; and Sarepta Therapeutics.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Butterfield reports no disclosure.

Emma Ciafaloni, MD, FAAN

Robert C. and Rosalyne H. Griggs Professor in Experimental Therapeutics of Neurologic Disease; Professor of Neurology, Pediatrics, and Obstetrics and Gynecology, University of Rochester, Rochester, New York

Relationship Disclosure: Dr Ciafaloni has received personal compensation for serving on advisory boards and speakers bureaus and/or as a consultant for Avexis, Inc; Biogen; Medscape; Pfizer Inc; PTC Therapeutics; Sarepta Therapeutics; and Strongbridge Biopharma plc. Dr Ciafaloni has received research/grant support from Biogen, the Centers for Disease Control and Prevention, CureSMA, the Muscular Dystrophy Association, the National Institutes of Health, Orphazyme, the Parent Project Muscular Dystrophy, the Patient-Centered Outcomes Research Institute, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, and the US Food and Drug Administration. Dr Ciafaloni has received royalties from Oxford University Press and personal compensation from Medlink for editorial duties.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Ciafaloni reports no disclosure.

Bruce H. Cohen, MD, FAAN

Professor of Pediatrics and Professor of Integrative Medicine, Northeast Ohio Medical University, Rootstown, Ohio; Director, Neurodevelopmental Science Center, Akron Children’s Hospital, Akron, Ohio

Relationship Disclosure: Dr Cohen has received personal compensation for being a speaker for the American Academy of Neurology and Stealth BioTherapeutics and for consulting for Mitobridge, Modis Pharmaceuticals, NeuroVive Pharmaceuticals, and Stealth BioTherapeutics. Dr Cohen has received research support from BioElectron Technology Corporation, Horizon Therapeutics, National Institutes of Health, Reata Pharmaceuticals, and Stealth BioTherapeutics. Dr Cohen has received publishing royalties from Elsevier.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Cohen reports no disclosure.

Mazen M. Dimachkie, MD, FAAN, FANA

Professor of Neurology, Executive Vice Chairman & Vice Chairman for Research Programs, Director, Neuromuscular Division - Department of Neurology Associate Director, Institute for Neurologic Discoveries, The University of Kansas Medical Center, Kansas City, Kansas

Relationship Disclosure: Dr Dimachkie has served as a consultant or on the speaker’s bureau for Alnylam Pharmaceuticals, Inc; Audentes Therapeutics, Inc; CSL Behring; Momenta Pharmaceuticals; Nufactor; RMS Medical Products; Sanofi Genzyme; Takeda; and Terumo Medical Company. Dr Dimachkie has received grants from Alexion Pharmaceuticals, Inc; Alnylam Pharmaceuticals, Inc; Amicus Therapeutics, Inc; BioMarin; Bristol-Myers Squibb Company; Catalyst Pharma; CSL Behring; Genentech, Inc; GlaxoSmithKline plc; Grifols, SA; the Muscular Dystrophy Association; The Myositis Association; the National Institutes of Health; Novartis AG; Sanofi Genzyme; Octapharma; Orphazyme; UCB, Inc; the US Food and Drug Administration/Orphan Products Development; and ViroMed Laboratories.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Dimachkie reports no disclosure.

Christopher T. Doughty, MD

Instructor of Neurology, Harvard Medical School; Associate Neurologist, Brigham and Women’s Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Doughty has received personal compensation as a CME lecturer for Oakstone and has received research/grant support from the National Institutes of Health for a clinical trials fellowship (U24NS107154).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Doughty discusses the unlabeled/investigational use of immunotherapy for the treatment of drug-induced inflammatory myopathies.

Namita A. Goyal, MD, FAAN

Associate Professor of Neurology, University of California Irvine, Irvine, California

Relationship Disclosure: Dr Goyal has received personal compensation for serving on the scientific advisory boards of Acceleron Pharma, Inc, Biogen, CSL Behring, Cytokinetics, and Mitsubishi Tanabe Pharma America, and for serving on a speaker’s bureau for CSL Behring.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Goyal reports no disclosure.

Amanda C. Guidon, MD

Instructor of Neurology, Harvard Medical School; Assistant in Neurology, Massachusetts General Hospital, Boston, Massachusetts

Relationship Disclosure: Dr Guidon has served on the medical advisory board for Alexion Pharmaceuticals, Inc, and as a consultant for Momenta Pharmaceuticals, Inc. Dr Guidon has received clinical trial research/grant support from Momenta Pharmaceuticals, Inc; the Patient-Centered Outcomes Research Institute; and Ra Pharmaceuticals, Inc, and publishing royalties from Oakstone Publishing, LLC.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Guidon discusses the unlabeled/investigational use of immunosuppressant therapies for the treatment of myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Mamatha Pasnoor, MD, FAAN

Associate Professor of Neurology, The University of Kansas Medical Center, Kansas City, Kansas

Relationship Disclosure: Dr Pasnoor has served on the advisory board of CSL Behring; as a consultant for Momenta Pharmaceuticals, Inc; and as a moderator for the University of California Irvine. Dr Pasnoor has received research/grant support from the National Institutes of Health (R01 DK064814).

Unlabeled Use of Products/Investigational Use Disclosure: Dr Pasnoor reports no disclosure.

Valeria A. Sansone, MD, PhD

Clinical and Scientific Director, Neurorehabilitation Unit, NEMO Clinical Center, Fondazione Serena Onlus; Professor of Neurology, University of Milan, Milan, Italy

Relationship Disclosure: Dr Sansone has served as a scientific consultant on advisory boards for AveXis, Inc; Biogen; PTC Therapeutics; Santhera Pharmaceuticals; and Sarepta Therapeutics and has received research/grant support from Telethon-Unione Italiana Lotta Alla Distrofia Muscolare.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Sansone reports no disclosure.

Mathula Thangarajh, MD, PhD, FAAN

Assistant Professor of Neurology, Virginia Commonwealth University, Richmond, Virginia

Relationship Disclosure: Dr Thangarajh has received research/grant support from the American Association of Neuromuscular and Electrodiagnostic Medicine.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Thangarajh reports no disclosure.

Kathryn R. Wagner, MD, PhD

Director, Center for Genetic Muscle Disorders, Kennedy Krieger Institute; Professor, Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland

Relationship Disclosure: Dr Wagner has received personal compensation for serving on the data safety monitoring board of FibroGen, Inc; the dose escalation committee of Wave Pharma; and as a consultant for Asklepios BioPharmaceutical, Inc., Dynacure, F. Hoffmann-La Roche AG, PTC Therapeutics, and Sarepta Therapeutics. Dr Wagner has received research/grant support from Acceleron Pharma, Inc; Catabasis; F. Hoffmann-La Roche AG; Fulcrum Therapeutics; Michael’s Cause; the National Institute of Child Health and Human Development; Pfizer Inc; Pietro’s Fight; and Ryan’s Quest.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Wagner reports no disclosure.

Conrad C. Weihl, MD, PhD

Professor of Neurology, Washington University School of Medicine, St. Louis, Missouri

Relationship Disclosure: Dr Weihl has received personal compensation for serving on the advisory boards of Acceleron Pharma, Inc and Sarepta Therapeutics and for serving as a consultant for Sarepta Therapeutics. Dr Weihl has given expert medical testimony in court cases. Dr Weihl has received research/grant support from the Myositis Association, the Muscular Dystrophy Association, the Myositis Association, and the National Institutes of Health.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Weihl reports no disclosure.

Matthew P. Wicklund, MD, FAAN

Professor of Neurology, University of Colorado, Aurora, Colorado

Relationship Disclosure: Dr Wicklund has received personal compensation for serving on the scientific advisory boards of Myonexus Therapeutics, Inc and Sarepta Therapeutics. Dr Wicklund has served on the editorial board of Muscle & Nerve, has held stock or stock options for Myonexus Therapeutics, Inc, and has received research/grant support as principal investigator of studies for Acceleron Pharma, Inc; the Muscular Dystrophy Association; and Orphazyme.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Wicklund discusses the unlabeled/investigational use of cell replacement therapies, gene editing, and viral vector gene therapy for the treatment of limb-girdle muscular dystrophies.

Self-Assessment and CME Test Writers

Douglas J. Gelb, MD, PhD, FAAN

Professor of Neurology, University of Michigan, Ann Arbor, Michigan

Relationship Disclosure: Dr Gelb has received royalties from MedLink, Oxford University Press, and UpToDate, Inc.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Gelb reports no disclosure.

Adam G. Kelly, MD, FAAN

Associate Professor of Neurology, Director of Teleneurology and Regional Neurology, University of Rochester, Rochester, New York

Relationship Disclosure: Dr Kelly has received personal compensation as CME editor of Neurology.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Kelly reports no disclosure.

Peer Reviewers

Continuum is a peer-reviewed journal. For each review article, at least two peer reviewers anonymous to the authors are selected to assess quality, balance, and clarity of articles. Critical reviews of the material at other stages of the development process may also be conducted. Upon receipt of final manuscripts, the editor-in-chief makes the final decision as to whether material is suitable for publication in Continuum.

We are thankful to the following peer reviewers of articles published during 2019 for the immense work they put in and their excellent assessment of manuscripts to help ensure that only the highest-quality information is published in Continuum:

Andrew Biondo, DO, FAAN, FAANEM

Christine Boutwell, MD

Michael Bradshaw, MD

Ali Hamedani, MD, MHS

Anna Hohler, MD, FAAN

Sushant Kale, MD

Shannon Kilgore, MD, FAAN

Karlo Lizarraga, MD, MS

Scott Lucchese, MD

Aaron Miller, MD, FAAN

Stephen Nelson Jr, MD, FAAN

David Roeltgen, MD, FAAN

Laura Powers, MD, FAAN

Gregory Van Stavern, MD, FAAN

© 2019 American Academy of Neurology.